Characterising BiologIC’s disruptive bioprocessing platform for synthetic biology including therapies, foods and diagnostics
Lead Participant:
BIOLOGIC TECHNOLOGIES LIMITED
Abstract
Humanity faces three enormous challenges: feeding 9.8 billion people by 2050, mitigating climate change and eliminating the existential threat of diseases including zoonotic pandemics.
BiologIC is developing the world's first biocomputer. BiologIC's ambition is to build a world leading UK biocomputing industry to unleash the full potential of synthetic biology. BiologIC's technology aims to revolutionise bioprocessing in the way the integrated circuit revolutionised information processing. The outcome would be a paradigm shift in the detection and mitigation of diseases, the production of foods, the development of new biofuels and biomaterials and DNA data processing.
BiologIC's breakthrough digital hardware architectures use multi-material 3D-printing to fabricate fluidics, electronics, thermals, optics and pneumatic circuits into integrated bioprocessors. These bioprocessors are assembled within biocomputing devices that increase the processing power of synthetic biology. The devices also incorporate a dense network of biosensors, such as pH and dissolved oxygen, generating rich data to drive adaptive workflows.
Products are being developed to advance applications in research, diagnostics, therapies such as new vaccines, cultured meat and biofuels and are designed to power the next generation of synthetic biology at scale.
The scope of work is to couple the performance of the bioprocesses with appropriate analytes and metrics to help monitor the quality of the biologic produced or detected under defined operating conditions. Establishing relations between the process and product would require bespoke, non-trivial analysis, possibly using different and complementary measurements.
The analysis will investigate and validate the feasibility of BiologIC's architectures and support development of high-throughput bioprocessing systems. In the longer term, this work is expected to underpin a scheme for continuous monitoring of product quality, leading to next generations of our 3D-printed devices.
BiologIC is developing the world's first biocomputer. BiologIC's ambition is to build a world leading UK biocomputing industry to unleash the full potential of synthetic biology. BiologIC's technology aims to revolutionise bioprocessing in the way the integrated circuit revolutionised information processing. The outcome would be a paradigm shift in the detection and mitigation of diseases, the production of foods, the development of new biofuels and biomaterials and DNA data processing.
BiologIC's breakthrough digital hardware architectures use multi-material 3D-printing to fabricate fluidics, electronics, thermals, optics and pneumatic circuits into integrated bioprocessors. These bioprocessors are assembled within biocomputing devices that increase the processing power of synthetic biology. The devices also incorporate a dense network of biosensors, such as pH and dissolved oxygen, generating rich data to drive adaptive workflows.
Products are being developed to advance applications in research, diagnostics, therapies such as new vaccines, cultured meat and biofuels and are designed to power the next generation of synthetic biology at scale.
The scope of work is to couple the performance of the bioprocesses with appropriate analytes and metrics to help monitor the quality of the biologic produced or detected under defined operating conditions. Establishing relations between the process and product would require bespoke, non-trivial analysis, possibly using different and complementary measurements.
The analysis will investigate and validate the feasibility of BiologIC's architectures and support development of high-throughput bioprocessing systems. In the longer term, this work is expected to underpin a scheme for continuous monitoring of product quality, leading to next generations of our 3D-printed devices.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| BIOLOGIC TECHNOLOGIES LIMITED | £24,000 | £ 24,000 |
Participant |
||
| LGC LIMITED | £26,000 | |
| INNOVATE UK |
People |
ORCID iD |
| Richard Vellacott (Project Manager) |